<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366801">
  <stage>Registered</stage>
  <submitdate>28/07/2014</submitdate>
  <approvaldate>5/08/2014</approvaldate>
  <actrnumber>ACTRN12614000831684</actrnumber>
  <trial_identification>
    <studytitle>Effects of a protein preload on glycaemia and gastric emptying over 4 weeks in patients with type 2 diabetes </studytitle>
    <scientifictitle>A randomized, single-blind, cross-over trial to evaluate the effects of a protein preload compared to placebo on glycaemia and gastric emptying over 4 weeks in patients with type 2 diabetes </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>25g whey protein in a chocolate flavoured drink (or control) taken as a 'preload', 30 min before meals, three times daily, for 4 weeks. Adherence will be monitored by a daily diary with checkboxes to fill in on taking the preload, and by weekly telephone calls.There will be a 2 week 'washout' period before crossing over to the alternate intervention (control or whey protein).</interventions>
    <comparator>'Diet' chocolate flavoured drink without whey protein.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Postprandial blood glucose concentrations following a potato meal taken at the beginning and end of 4 weeks intervention.</outcome>
      <timepoint>0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 210 and 240 min after the meal</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Gastric emptying of a potato meal taken at the beginning and end of 4 weeks intervention, measured by scintigraphy.</outcome>
      <timepoint>Images taken every 15 min after the meal for 240 min.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fructosamine concentration in serum</outcome>
      <timepoint>Measured at the beginning and end of the active and placebo intervention periods.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Glycated haemoglobin in serum</outcome>
      <timepoint>Measured at the beginning and end of the active and placebo intervention periods.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with type 2 diabetes managed by diet alone</inclusivecriteria>
    <inclusiveminage>25</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	Significant medical disorders (other than diabetes); 
2.	Significant gastrointestinal symptoms or history of gastrointestinal surgery (other than appendicectomy or cholecystectomy);
3.	Intake of &gt;20 g alcohol on a daily basis or cigarette smoking; 
4.	Current use of medications which may affect gastrointestinal function or appetite (e.g. prokinetic drugs, orlistat, tricyclic antidepressants);
5.	Current pregnancy or lactation;
6.	Inability to prepare meals, or meet dietary requirements, (including frequent dining out (&gt;2x/week)) and widely fluctuating exercise patterns; 
7.	Inability or unwillingness to perform capillary blood glucose monitoring;
8.	Exposure to radiation as part of a research study in the preceding 12 months.
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation is not concealed</concealment>
    <sequence>Computer random number generator</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>False</masking2>
    <masking3>False</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>8/10/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate>24/12/2009</actualenddate>
    <samplesize>14</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Adelaide</primarysponsorname>
    <primarysponsoraddress>North Terrace, Adelaide SA 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Diabetes Australia Research Trust</fundingname>
      <fundingaddress>Diabetes Australia
GPO BOX 3156
CANBERRA  ACT  2601
</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients are randomised to receive 4 weeks treatments with a 25g whey protein 'preload' taken 30 min before each of the 3 main meals daily for 4 weeks, or placebo. After a 2 week 'washout' period, they cross over to the alternate treatment. They will attend the hospital for a test meal of radiolabelled mashed potato at the beginning and end of each intervention period, to evaluate whether the capacity of the protein preload to lower blood glucose concentrations and slow gastric emptying after the meal are sustained over 4 weeks.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Royal Adelaide Hospital
North Terrace
Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate>26/07/2007</ethicapprovaldate>
      <hrec>RAH protocol number 060823</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Chris Rayner</name>
      <address>Discipline of Medicine
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000
</address>
      <phone>+61 8 82222916</phone>
      <fax />
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Chris Rayner</name>
      <address>Discipline of Medicine
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax />
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Chris Rayner</name>
      <address>Discipline of Medicine
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax />
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Chris Rayner</name>
      <address>Discipline of Medicine
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax />
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>